Articles non-alloreactive engineered T cells for adoptive immunotherapy. Thus, ATOs are a standardized and highly efficient in vitro model of human T cell development that is readily amenable to genetic manipulation and may permit new approaches for the study of human T cell development.
studies of human t cell development require robust model systems that recapitulate the full span of thymopoiesis, from hematopoietic stem and progenitor cells (hsPcs) through to mature t cells. existing in vitro models induce t cell commitment from human hsPcs; however, differentiation into mature cd3 + tcr- + single-positive cd8 + or cd4 + cells is limited. We describe here a serum-free, artificial thymic organoid (Ato) system that supports efficient and reproducible in vitro differentiation and positive selection of conventional human t cells from all sources of hsPcs. Ato-derived t cells exhibited mature naive phenotypes, a diverse t cell receptor (tcr) repertoire and tcr-dependent function. Atos initiated with tcr-engineered hsPcs produced t cells with antigenspecific cytotoxicity and near-complete lack of endogenous tcr V expression, consistent with allelic exclusion of V-encoding loci. Atos provide a robust tool for studying human t cell differentiation and for the future development of stem-cellbased engineered t cell therapies.
Due to the spatiotemporal complexity of T cell development in the thymus, in vitro models of T cell differentiation have thus far been unable to fully recapitulate human T cell development. A major advance was the discovery that mouse stromal cell lines expressing a Notch ligand could support in vitro T cell differentiation from mouse or human HSPCs, as in the classic OP9-DL1 coculture system [1] [2] [3] . In this and similar monolayer systems, human cord blood (CB) HSPCs undergo T lineage commitment and rapid early T cell differentiation to generate CD7 + pro-T cells, followed by CD4 'immature single-positive' (ISP) precursors around day 20, and CD4 + CD8 + double-positive (DP) precursors around day 30 (ref. 3) . Despite this, positive selection of T cell precursors with productively rearranged TCRs is impaired in OP9-DL1 co-culture, and consequently few CD3 + CD8 + or CD4 + SP T cells develop [2] [3] [4] [5] . By day 60-70 of co-culture on OP9-DL1, mature CD8 SP cells represent at most 2-4% of the total amount of cultured cells 5 . Improved maturation has been reported using CD34 + HSPCs isolated from the human postnatal thymus 6 a population largely composed of lineage-committed pro-T cells 7 . However, T cell maturation on OP9-DL1 is particularly inefficient using mobilized peripheral blood (PB) and bone marrow (BM) HSPCs, the latter giving ~10% of the DP and CD3 + TCR-αβ + cell yields seen with CB cultures 8 .
Generation of mature t cells from human hematopoietic stem and progenitor cells in artificial thymic organoids
We and others have shown that three-dimensional (3D) organoid systems using mouse [9] [10] [11] or human 12 primary thymic stroma support improved positive selection and maturation of human T cells in vitro. However, these systems are difficult to use given their dependence on primary thymic tissue and their high experimental variability.
We report here the development of an ATO system based on a delta-like canonical Notch ligand 1 (DLL1)-expressing stromal cell line and serum-free, off-the-shelf components that support robust differentiation, positive selection and maturation of human CD3 + TCR-αβ + CD8 SP and CD4 SP T cells from CB, BM and PB CD34 + HSPCs. Differentiation was efficient whether initiated with CD34 + CD3 − HSPCs, hematopoietic stem cells (HSCs) or lymphoid progenitors. T cell differentiation in ATOs followed a phenotypic progression that closely recapitulated human thymopoiesis, and it was associated with long-term maintenance of CD34 + T cell progenitors.
Both CD3 + CD8 SP and CD3 + CD4 SP mature T cells that developed in ATOs showed an antigen-naive phenotype, a diverse TCR repertoire, and cytokine production and proliferation in response to antigenic stimuli. ATOs also supported highly efficient differentiation of TCR-engineered, antigen-specific T cells from HSPCs that were transduced with constructs encoding MHC class I-restricted TCRs specific for the tumor-associated antigens NY-ESO-1 and MART-1. ATO-derived engineered T cells showed a naive phenotype, as well as in vitro and in vivo antigen-specific cytotoxicity. Moreover, these cells lacked endogenous TCR Vβ expression, consistent with induction of allelic exclusion by the transduced TCR-encoding construct during early T cell differentiation, suggesting a new approach for the generation of potentially demonstrated the formation of dense tissue architecture with abundant lymphoid cells ( Supplementary Fig. 1) , clusters of which expressed CD3 (Fig. 1e) .
Each ATO typically generated ~2 × 10 6 total cells at 6 weeks ( Fig. 1f) ; however, cell yield per HSPC was inversely related to the number of HSPCs seeded and to the ratio of HSPCs to stromal cells (Supplementary Fig. 2a ). Frequencies of precursor and mature T cells in ATOs were similar across initial HSPC numbers and ratios ( Supplementary Fig. 2b) , with the exception of ATOs that were generated with large numbers of stromal cells (6 × 10 5 per ATO), which showed impaired T cell maturation. Thus, smaller ATOs (typically 7,500 HSPCs and 1.5 × 10 5 stromal cells at a 1:20 ratio) were used for further experiments, and they showed high reproducibility of cell output and T cell differentiation across technical replicates (n = 11), independent of the lot of B27 used ( Supplementary Fig. 3a-d) . Of translational relevance, efficient T cell differentiation and cell output was also seen in ATOs that were cultured either with xeno-free B27 ( Supplementary Fig. 3e ,f) or using irradiated MS5-hDLL1 stromal cells ( Supplementary  Fig. 3g-j) . Recovery of hematopoietic cells generated in ATOs after simple mechanical disruption and filtration resulted in >99% CD45 + hematopoietic cells ( Supplementary Fig. 3k ).
Direct comparison of ATOs to the OP9-DL1 monolayer culture system revealed a similar efficiency of T lineage commitment (percentage CD7 + CD5 + cells) but markedly superior generation of both DP and CD3 + TCR-αβ + T cells at 4 and 6 weeks ( Fig. 2a-d and Supplementary Fig. 4 ). Improved positive selection was particularly evident in the prevalence of mature CD3 + TCR-αβ + CD8 SP T cells in ATOs but not in OP9-DL1 monolayers ( Fig. 2b-d and Supplementary Fig. 4) . Crossover experiments testing the effect of cell culture variables revealed that optimal positive selection and T cell maturation required all three components of the ATO system-3D structure, MS5-hDLL1 stromal cells and RB27 medium-as neither monolayer cultures using ATO components nor OP9-DL1 cells in 3D organoids supported T cell development ( Supplementary Fig. 5 ). The parental MS5 cell line (which lacks DLL1 expression) did not support T cell development in either monolayer or 3D cultures, consistent with a requirement for Notch signaling for T cell development ( Supplementary Fig. 5a ).
thymopoiesis and naive t cell development in Atos
We next compared T cell differentiation in ATOs to that in the postnatal human thymus. Week 12 CB ATOs showed a similar frequency of CD34 + pro-T cells and T-lineage-committed (CD5 + CD7 + ) cells to those in the thymus (Fig. 3a) . Similarly to that seen in the thymus, most of the CD3 + T cells in ATOs were TCR-αβ + (Fig. 3a) . The frequencies of mature CD3 + TCR-αβ + CD8 SP and CD4 SP T cells in ATOs increased between weeks 6 and 12 ( Fig. 3b and Supplementary Fig. 6a ) and showed a reversed CD4:CD8 ratio as compared to that seen in the thymus.
Similarly to that observed in the thymus, ATO-derived CD3 + TCR-αβ + CD8 SP and CD3 + TCR-αβ + CD4 SP T cells transited from a DP-like 'immature naive' (CD45RA − CD45RO + CD27 + CCR7 − CD1A hi ) to a 'mature naive' (CD45RA + CD45RO − CD27 + CCR7 + CD1a lo ) phenotype 21, 22 (Fig. 3c and Supplementary  Fig. 6a-c) . Both immature and mature naive T cell subsets co-expressed CD62L and CD28, with subset co-expression of CD127 and CD31, the latter of which is associated with recent a b
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Week thymic emigrant T cells in the blood 23 (Supplementary Fig. 6b,c) . The activation marker CD25 was not expressed on ATO-derived CD8 SP T cells, but it was observed on a subset of CD4 SP T cells ( Supplementary Fig. 6b,c) . Taken together, these data show remarkable fidelity of T cell differentiation in ATOs as compared to that in the human thymus, which culminates in the emergence of naive T cells that are phenotypically similar to those in the thymus and blood 24, 25 . Given the absence of thymic epithelial cells, and the late emergence and relatively low frequencies of mature CD4 SP T cells, we postulated that MHC class II-mediated positive selection may rely on the development of rare dendritic cells in ATOs. Indeed, HLA-DR + cells were present in ATOs at low frequencies, and these included monocytes, B cells, and plasmacytoid, CLEC9A + and CD1c + dendritic cells ( Supplementary Fig. 6d ), all of which were also present in the thymus, in agreement with previous reports 26, 27 (Supplementary Fig. 6e ).
t cell differentiation from multiple hsPc sources and subsets
In addition to CB, we observed efficient T cell differentiation in ATOs from clinically relevant HSPC sources, i.e., adult BM, granulocyte-colony-stimulating factor (G-CSF)-mobilized PB (MPB) and nonmobilized PB ( Fig. 4a-d and Supplementary  Fig. 7a,b) . Kinetics of T cell differentiation varied between cells from different sources ( Fig. 4c) , with thymic CD34 + cells predictably showing the fastest differentiation; however, T cell output was similar irrespective of the source (Fig. 4d ). Enriched HSC fractions (Lin − CD34 + CD38 − ) 28 from CB, BM or MPB also demonstrated efficient T cell differentiation in ATOs (Fig. 4e,f and Supplementary Fig. 7c,d ).
ATOs also supported T cell differentiation from highly purified lymphoid progenitors that were isolated from adult BM ( Fig. 4g,h) . Lymphoid-primed multipotent progenitors (LMPPs) 29 and CD24 − common lymphoid progenitors 30 (CLPs) generated T cells to a greater extent than unfractionated CD34 + Lin − HSPCs (Supplementary Fig. 7e,f) . In contrast, CD24 + CLPs, which possess primarily B and NK cell potential 30, 31 , resulted in poor T cell output in ATOs (Fig. 4g,h and Supplementary Fig. 7e ). Thus, ATOs can serve as a tool for evaluating T lineage potential in HSPC populations.
tcr diversity and function of Ato-derived t cells
Similarly to that observed in the thymus, RAG1 and RAG2 were expressed in DP T cells derived from ATOs, consistent with rearrangement of TCR-encoding genes (hereafter referred to as TCR genes) ( Supplementary Fig. 8a) . Flow cytometric analysis of ATO-derived CD3 + TCR-αβ + CD8 SP ( Fig. 5a ) and CD3 + TCRαβ + CD4 SP ( Supplementary Fig. 8b ) T cells revealed notably similar usage of TCR Vβ families to those of corresponding naive T cells from human thymi. Physiological TCR diversity was confirmed by deep sequencing of the sequences encoding the TCR Vα and Vβ complementarity-determining region 3 (CDR3) regions in ATO-derived CD3 + TCR-αβ + CD8 SP T cells and their comparison to the sequences from both thymic and PB naive CD8 SP T cells ( Fig. 5b,c) . Notably, we did not observe skewed Vα or Vβ usage in ATO-derived T cells, which argued against the predominance of unconventional T cell lineages or clonally expanded T cells.
CD8 SP T cells isolated from ATOs demonstrated polyfunctional production of interferon (IFN)-γ, tumor necrosis factor (TNF)-α and IL-2 in response to treatment with phorbol 12-myristate 13-acetate (PMA) and ionomycin ( Fig. 5d) , showed upregulation of CD25 and 4-1BB, and proliferated in response to treatment with anti-CD3, anti-CD28 and IL-2 ( Fig. 5e,f) . CD4 SP cells that were freshly isolated from ATOs produced IFN-γ and IL-2 in response to PMA and ionomycin treatment, and they proliferated in response to treatment with anti-CD3, anti-CD28 and IL-2 ( Supplementary Fig. 8c-e ).
In vitro generation of naive tcr-engineered t cells in Atos
We next explored whether ATOs could be used for the in vitro generation of naive TCR-engineered T cells. CB CD34 + CD3 − HSPCs were transduced with a lentiviral vector encoding codon-optimized α and β chains of a HLA-A*02:01-restricted TCR specific for the NY-ESO-1 157-165 peptide 32 (hereafter referred to as TCR-transduced HSPCs). At 7 weeks of culture, ATOs derived from TCR-transduced cells showed a similar frequency of CD7 + CD5 + T lineage cells as those from the mocktransduced controls but markedly increased CD3 + TCR-αβ + T cells, the majority of which expressed the exogenous TCR, as detected by a tetramer or an antibody specific for the exogenous Vβ13.1 chain (Fig. 6a) . The frequency of CD3 + TCR-αβ + CD8 SP T cells that were generated from TCR-transduced HSPCs was similar to that of the CD3 + TCR-αβ + CD8 SP T cells from mock-transduced HPSCs; however, TCR transduction resulted in accelerated maturation from an immature (CD45RA − CD45RO + CD27 − CCR7 − CD1a hi ) to a mature (CD45RA + CD45RO − CD27 + CCR7 + CD1a lo ) naive T cell phenotype (Fig. 6a) . Because antigen-specific T cells with an unconventional CD8-αα phenotype have been reported in the OP9-DL1 system 33 , we confirmed that tetramer + T cells from ATOs displayed a conventional CD8-αβ phenotype and lacked expression of CD16 or CD56, markers associated with NK cells and innate-like T cells ( Fig. 6b) .
TCR transduction also significantly enhanced cell yield from ATOs (average ~500 cells per HSPC) ( Fig. 6c) , the majority of which were tetramer + CD3 + CD8 SP T cells. Thus, by 7 weeks of culture a single ATO that was initiated with 7,500 TCR-transduced HSPCs generated on average ~4 × 10 6 cells, of which approximately 15% (6 × 10 5 ) were mature naive tetramer + CD3 + CD8 SP CD45RA + CD45RO − antigen-specific T cells (Fig. 6a,c) . cells   0  1  2  3  4  5  6  7  8  9  10  11  12  13  0  1  2  3  4  5  6  7  8  9  10  11  12  13   0  1  2  3  4  5  6  7  8  9  10  11  12  13  0  1  2  3  4  5  6  7  8  9  10  11  12  13  0  1  2  3  4  5  6  7  8  9  10  11 ATO-derived antigen-specific CD8 SP T cells showed polyfunctional cytokine production (IFN-γ, TNF-α and IL-2), degranulation (as assessed by CD107a membrane mobilization; Fig. 6d ) and proliferation ( Fig. 6e ) in response to artificial antigen-presenting cells (aAPCs) expressing CD80 and a cognate HLA-A*02:01-NY-ESO-1 single-chain trimer but not to irrelevant HLA-A*02:01-MART-1-expressing aAPCs or to parental K562 cells. Furthermore, these T cells could be expanded by treatment with anti-CD3-and anti-CD28-coated beads and either IL-2 or IL-7 and IL-15 ( Fig. 6f) . A previous report of TCR-engineered T cells that were derived using the OP9-DL1 system reported loss of CD8-β expression following repeated in vitro stimulation 33 ; although a subpopulation of ATO-derived tetramer + CD8 SP T cells was CD8-β − following re-stimulation with anti-CD3-and anti-CD28-coated beads, the majority of cells maintained a conventional CD8-αβ phenotype (Supplementary Fig. 9a) .
Flow cytometric analysis of Vβ diversity in ATO-derived TCRengineered T cells revealed that >98% of tetramer + CD3 + CD8 SP T cells expressed only the exogenous Vβ13.1 segment ( Fig. 6g  and Supplementary Fig. 9b ), suggesting that allelic exclusion of both endogenous Vβ loci occurred during differentiation of TCR-engineered T cells in ATOs.
To test whether these findings could be extended beyond the NY-ESO-1-specific TCR, we generated ATOs using CB HSPCs that were transduced with a construct expressing a HLA-A*02:01restricted TCR specific for MART-1 (ref. 34) . Tetramer + CD3 + CD8 SP cells isolated from these ATOs demonstrated a naive T cell phenotype (Supplementary Fig. 9c ), and they upregulated IFN-γ and mobilized CD107a in response to MART-1 but not NY-ESO-1 aAPCs (Supplementary Fig. 9d) .
We next tested antigen-specific cytotoxicity of ATO-derived TCR-engineered T cells. Purified NY-ESO-1-specific CD8 SP T cells that were isolated from ATOs of TCR-transduced HSPCs and activated for 36 h potently induced apoptosis in cell lines expressing the cognate peptide-MHC complex (pMHC) (either K562 cells transduced with an HLA-A*02:01-NY-ESO-1 singlechain trimer (SCT) or the HLA-A*02:01-U266 multiple myeloma cell line, which endogenously expresses NY-ESO-1), but they showed little activity against parental K562 cells or K562 cells that expressed an irrelevant HLA-A*02:01-MART-1 SCT ( Fig. 6h and Supplementary Fig. 9e ). Consistent with their naive state, prior activation of ATO-derived antigen-specific T cells was required for cytotoxicity. Loss of antigen specificity was not observed following prolonged (14 d ) in vitro expansion, indicating retention of a conventional T cell phenotype (Supplementary Fig. 9f ); furthermore, cytotoxicity was similar to that of TCR-transduced PB CD8 + T cells that had been expanded for the same amount of time (Supplementary Fig. 9f ). Consistent with these results, ATO-derived TCR-engineered T cells were able to significantly control disease progression in immunodeficient NSG mice that had been subcutaneously engrafted with antigen-expressing K562 tumors (Fig. 6i) .
discussion
We present here an in vitro system that efficiently initiates and sustains the normal stages of T cell commitment and differentiation from human HSPCs, culminating in the production of mature, naive CD3 + TCR-αβ + CD8 SP and CD3 + TCR-αβ + CD4 SP T cells that closely resemble naive T cells from the thymus and blood. Enhanced positive selection of T cell in ATOs, relative to that in existing methods, was strictly dependent on both the 3D structure and the stromal cell line used, as monolayer cultures set up with ATO components resulted in inefficient T cell maturation, as did 3D organoid cultures using OP9-DL1 cells. We have, however, observed mature T cell development in ATOs using DLL1-transduced immortalized human BM stromal cells, and although efficiency is lower than that for MS5-hDLL1 cells, this indicates that neither speciesspecific nor MS5-specific factors underlie T cell positive selection in ATOs. We also predict that other Notch ligands, such as DLL4, should be effective in driving T cell development in ATOs.
A specific role for 3D structure in the positive selection of T cells is consistent with the reported ability of FTOCs and reaggregated primary thymic stromal organoids to permit T cell maturation, even though it occurs at low efficiency [10] [11] [12] . 3D interactions may support positive selection by increasing the valence and/or duration of contact between T cell precursors and the selective ligands (such as pMHC), facilitating cross-talk between stromal and hematopoietic cells or exerting developmental signals on T cell precursors through mechanical forces and/or metabolic gradients not otherwise possible in 2D cultures. The formation of thymic-like spatial niches that segregate developing T cells from stromal signals and/or Notch ligands during development may be another possible mechanism at work in ATOs. In the absence of thymic epithelial cells in ATOs, we hypothesize that selective MHC I ligands for the positive selection of CD8 SP cells are ubiquitously presented by hematopoietic cells within the ATOs, as has been suggested in the OP9-DL1 system 6 but that positive selection of CD4 SP cells occurs via MHC class II presentation by dendritic cells that develop within ATOs, with their rarity possibly underlying the bias toward CD8 + T cell development in this system. The nature of these and other specific mechanisms of T cell selection can now be readily investigated using the ATO system in conjunction with model TCR-antigen systems.
Differentiation of TCR-engineered T cells from HPSCs has been reported using the OP9-DL1 system; however, as with nontransduced HSPCs, positive selection and generation of mature CD3 + T cells is impaired (typically representing only 0-2% of the cells in the cultures), with the highest efficiencies being achieved using thymic CD34 + cells 33, 35, 36 . In comparison, ATOs strongly supported the differentiation and positive selection of mature CD3 + TCR-engineered T cells from CB HSPCs.
In contrast to TCR-transduced PB T cells, which require activation and prolonged expansion, in vitro generation of naive antigenspecific T cells may offer distinct therapeutic advantages for adoptive cell therapy based on studies correlating earlier T cell differentiation state with in vivo efficacy 24, 37, 38 . Nontransduced and TCRtransduced ATOs showed accumulation of naive CD3 + CD8 SP T cells over time, with concomitant decrease in DPs, consistent with the absence of T cell egress. Despite this, mature T cells in ATOs retained a naive phenotype, absence of activation markers, and required activation-priming for effective cytotoxicity. TCR transduction of HSPCs also resulted in near-complete allelic exclusion of endogenous Vβ TCR loci, consistent with findings from in vivo studies of TCR-transduced mouse and human HSPCs 34, 39, 40 . The expression of potentially alloreactive endogenous TCRs on engineered PB T cells is a major barrier to the development of off-the-shelf adoptive T cell therapies, and current approaches to mitigate donor T cell alloreactivity, such as gene editing [41] [42] [43] or the use of virus-specific T cells 44 , require extensive cell manipulation, which could potentially compromise function. We illustrate here that ATOs can be used to exploit developmental allelic exclusion of endogenous TCR expression as a novel strategy for generating potentially non-alloreactive antigen-specific T cells for immunotherapy. ATOs are thus a new tool for the study and development of stem-cell-based engineered T cell therapies, given the ease of genetically manipulating both hematopoietic and stromal compartments, and the ability to produce naive, unperturbed antigen-specific T cells.
Finally, the ATO system offers technical simplicity, reproducibility and potential scalability. The use of serum-free medium avoids the marked variability observed in monolayer systems 13 , and the ability to maintain ATOs intact for the duration of culture (up to 20 weeks) with simple medium changes reduces labor through avoiding the frequent transfer of cells onto fresh stromal cells that are required by monolayer systems 2, 3, 13 . The simplicity of the ATO system permits straightforward adoption of the method in laboratories interested in studying human T cell development and engineered T cell therapies.
methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. and, with B.C., assisted with in vivo experiments; S.L. assisted with ATO analysis and T cell functional assays; K.K. assisted with ATO cultures; Y.Z. performed human specimen processing and cultured the cell lines; E.H.G. and D.B.K. provided critical reagents and conceptual advice and edited the manuscript; M.T.B. and D.B. devised the approach for, and performed, TCR repertoire sequencing analysis and provided critical reagents; and G.M.C. and A.M.-H. co-directed the project and co-wrote the manuscript. online methods A protocol to aid users accompanies this article and is available as Supplementary Protocol; it has also been deposited in the Protocol Exchange 45 .
Isolation of human CD34 + CD3 − HSPCs. Neonatal umbilical CB was obtained from discarded cord and placental units from deliveries at UCLA. BM was obtained from healthy adult donors (ages 18-51) through discarded material from allogeneic BM donor harvests at UCLA or was purchased from AllCells Inc. (Alameda, CA). G-CSF-mobilized PB was obtained from consenting healthy adult donors (ages 44-60) who were undergoing apheresis for allogeneic stem cell transplant donation at UCLA. Nonmobilized PB was obtained from healthy adult donors through the UCLA CFAR Virology Core. All tissue samples were obtained under UCLA Institutional Review Board (IRB)approved protocols or exemptions. All samples were enriched for mononuclear cells by Ficoll-Paque (GE Healthcare Life Sciences, Pittsburgh, PA) gradient centrifugation followed by positive selection of CD34 + cells by magnetic cell sorting (MACS) using the CD34 MicroBead Kit UltraPure (Miltenyi Biotec, Auburn, CA). CD34 + -cell-enriched fractions were cryopreserved after MACS, unless otherwise noted. Prior to use, cells were thawed, and the residual T cells were depleted by FACS by sorting for CD34 + CD3 − cells, which were immediately seeded into ATOs or transduced as described below. In some experiments, HSCs were enriched by FACS for Lin − CD34 + CD38 − cells before seeding in ATOs. HSPCs used in TCR transduction experiments were from HLA-A*02:01 + CB units. High-resolution HLA-A2 typing was performed by the UCLA Immunogenetics Center using sequence-specific oligonucleotide (SSO) beads.
Isolation of human bone marrow progenitor subsets. CD34 +
HSPCs were enriched from fresh BM aspirates, as described above, and immediately sorted by FACS for stem and progenitor populations based on positive expression of CD45 and the absence of expression of lineage markers (CD3, CD14, CD19, CD56 and CD235a; referred to as 'Lin − ') combined with the following markers: total HSPCs (CD34 + ), HSC (CD34 + CD38 − CD 45RA − ) 28, 46 , LMPP (CD34 + CD38 + CD45RA + CD10 − CD62L hi ) 29 , CD24 − CLP (CD34 + CD38 + CD45RA + CD10 + CD24 − ) 30 and CD24 + CLP (CD34 + CD38 + CD45RA + CD10 + CD24 + ) 30, 31 .
Isolation of human thymocytes. Postnatal human thymi were obtained under an IRB exemption as discarded waste from patients undergoing cardiac surgery at Children's Hospital Los Angeles (CHLA). Thymic fragments were finely dissected in RPMI medium (Cellgro) and disrupted by pipetting to release thymocytes into suspension, followed by passage through a 70-µm nylon strainer. Cells were analyzed fresh on the same or the following day. Flow cytometry analysis of thymic and ATO-derived T cell progenitors used the following surface phenotypes: early thymic progenitor (ETP; CD34 + CD7 − CD1a − ), CD1a − pro-T (CD34 + CD7 + CD1a − ) and CD1a + pro-T (CD34 + CD7 + CD1a + ) cells 7 , or CD5 − pro-T (pro-T1; CD34 + CD7 + CD5 − ) and CD5 + pro-T (pro-T2; CD34 + CD7 + CD5 + ) cells 20 . Thymic and ATO-derived T cells and precursors were defined as CD14 − CD56 − in combination with the following phenotypes: total T lineage cells (CD7 + CD5 + ), double negative (DN; CD4 − CD8 − ), CD4 ISP (CD5 + CD4 + CD3 − ), double positive (DP; CD4 + CD8 + ), CD8 SP (CD3 + TCRαβ + CD8 + CD4 − ), CD4 SP (CD3 + TCR-αβ + CD8 − CD4 + ), immature naive (CD45RA − CD45RO + that were CD8 SP or CD4 SP) and mature naive (CD45RA + CD45RO − that were CD8 SP or CD4 SP). Immature and mature naive phenotypes were confirmed by co-staining for CD1a, CD27, CD28 and CCR7.
Isolation of primary human T cells.
Thymic T cells were isolated from thymocyte preparations as described above, and PB and CB CD8 + T cells were isolated from mononuclear cell fractions as described above. CD8 + T cell isolation from all sources was by magnetic bead enrichment for CD8 SP T cells using the CD8 + T cell Isolation Kit (Miltenyi Biotec). In some experiments, thymic T cells were further purified by FACS to deplete CD4 ISP or DP precursors, and PB T cells were further purified by FACS to isolate naive T cells (CD45RO − CCR7 + ).
Cell lines. The MS5 mouse stromal cell line 15 was obtained as a gift from Laure Coulombel and is commercially available from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig Germany (DSMZ no. ACC 441). To generate MS5-hDLL1 cells, we transduced MS5 cells with a lentiviral vector encoding human DLL1 and enhanced green fluorescent protein (eGFP). The top 5% of the cells with the highest expression of GFP were sorted by FACS and passaged in Dulbecco's modified Eagle's medium (DMEM; Cellgro) + 10% FCS (Gemini). Stable expression was confirmed by flow cytometry for GFP expression after several weeks of culture, and DLL1 expression was confirmed by qRT-PCR and DNA sequencing; absence of mycoplasma contamination was confirmed. The OP9-DL1 cell line 1 (expressing mouse Dll1) was a gift from Dr. Juan Carlos Zúñiga-Pflücker (University of Toronto) and was passaged in MEMα (ThermoFisher Scientific, Grand Island, NY) + 20% FBS in 0.1% gelatin-coated flasks. The K562 cell line was obtained from the ATCC and maintained in RPMI + 10% FCS. K562 aAPCs were generated by co-transduction of K562 cells with lentiviral vectors encoding full-length human CD80 and HLA-A*02:01-β2M-NY-ESO-1 157-165 or HLA-A*02:01-β2M-MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] SCTs (provided by D.B.). K562 target cells were created by transduction of constructs encoding either of the SCTs without CD80. Luciferase-K562 target cells were created by sequential transduction of K562 cells with a firefly-luciferase-expressing lentiviral vector (provided by D.B.K.) followed by either of the SCT vectors. K562 transductants were FACS-sorted before use. The U266 multiple myeloma cell line was a gift from Dr. John Chute (UCLA) and maintained in RPMI + 10% FCS.
Artificial thymic organoid (ATO) cultures. MS5-hDLL1 (or MS5 or OP9-DL1, as noted) cells were harvested by trypsinization and resuspended in serum-free ATO culture medium ('RB27'), which was composed of RPMI 1640 (Corning, Manassas, VA), 4% B27 supplement (ThermoFisher Scientific, Grand Island, NY), 30 µM l-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich, St. Louis, MO) reconstituted in PBS, 1% penicillin-streptomycin (Gemini Bio-Products, West Sacramento, CA), 1% Glutamax (ThermoFisher Scientific, Grand Island, NY), 5 ng/ml recombinant human FLT3 ligand (rhFLT3L) and 5 ng/ml recombinant human IL-7 (rhIL-7) (Peprotech, Rocky Hill, NJ). RB27 was made fresh weekly. 4% XenoFree B27 was substituted for B27 in the indicated experiments. Depending on the experiment, 1.5 × 10 5 to 6 × 10 5 MS5-hDLL1 cells were combined with 3 × 10 2 to 1 × 10 5 purified CD34 + CD3 − cells (or other HSPC populations, as indicated) per ATO in 1.5-ml microcentrifuge tubes and centrifuged at 300g for 5 min at 4 °C in a swinging-bucket centrifuge. Supernatants were carefully removed, and the cell pellet was resuspended by brief vortexing. For each ATO, a 0.4-µm Millicell Transwell insert (EMD Millipore, Billerica, MA; Cat. PICM0RG50) was placed in a 6-well plate containing 1 ml RB27 per well. To plate ATOs, inserts were taken out and rested on the edge of the plate to drain the excess medium. The cell slurry was adjusted to 5 µl per ATO, drawn up in with a 20-µl pipet tip and plated by forming a drop at the end of the pipet tip that was then gently deposited onto the cell insert. The cell insert was placed back in the well containing 1 ml RB27. Medium was changed completely every 3-4 d by aspiration from around the cell insert followed by replacement with 1 ml fresh RB27 + cytokines. ATOs were cultured in this fashion for up to 20 weeks. At the indicated times, ATO cells were harvested by adding FACS buffer (0.5% BSA and 2 mM EDTA in PBS) to each well and briefly disaggregating the ATO by pipetting with a 1 ml 'P1000' pipet tip, followed by passage through a 50-µm nylon strainer. In some experiments, single-cell suspensions of MS5-hDLL1 cells were γ-irradiated at the indicated doses before use in ATOs.
T cell monolayer co-cultures. OP9-DL1 monolayer cultures were set up as previously described 1, 3, 13 . Briefly, OP9-DL1 cells were seeded into 0.1% gelatin-coated 12-well plates 1-2 d before use to achieve 70-80% confluence. Medium was aspirated from monolayers, and 1.5 × 10 4 FACS-purified CD34 + CD3 − HSPCs were plated on stromal monolayers in 2 ml of medium composed of MEMα, 20% FBS, 30 µM l-ascorbic acid, 5 ng/ml rhFLT3L and 5 ng/ml rhIL-7. In some experiments, MS5 or MS5-hDLL1 cells were substituted for OP9-DL1 cells, and RB27 was substituted as the culture medium. Cells were transferred to new stromal cell monolayers every 4-5 d by harvesting cells, filtering them through a 50-µm nylon strainer and re-plating them in fresh medium. When the cells reached confluence, they were split into multiple wells containing fresh stromal layers.
Lentiviral vectors and transduction.
The full-length coding sequence of human DLL1 was cloned by RT-PCR from a human universal reference RNA set (Agilent Technologies, Santa Clara, CA) into the third-generation lentiviral vector pCCL-c-MNDU3-X-IRES-eGFP 34 (provided by D.B.K.). Human CD80 was similarly cloned into pCCL-c-MNDU3. The third-generation lentiviral vector encoding the codon-optimized α and β (Vb13.1) chains of a TCR specific for HLA-A*02:01-NY-ESO-1 157-165 (derived from the 1G4 TCR clone 47 ) has previously been described 32 and was a gift from Dr. Antoni Ribas (UCLA). The codon-optimized HLA-A*02:01-MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -specific TCR (derived from the F5 TCR clone 48 ) was provided by D.B.K. Coding sequences for HLA-A*02:01-β2-M-NY-ESO-1 157-165 and HLA-A*02:01-β2-M-MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] SCTs were provided by D.B. and subcloned into the pCCL-c-MNDU3-X-IRES-mStrawberry lentiviral vector. Packaging and concentration of lentivirus particles was performed as previously described 32 . Briefly, 293T cells (ATCC) were co-transfected with a lentiviral vector plasmid, pCMV-R8.9, and pCAGGS-VSVG using TransIT 293T (Mirus Bio, Madison, WI) for 17 h followed by treatment with 20 mM sodium butyrate for 8 h, followed by generation of cell supernatants in serum-free UltraCulture for 48 h. Supernatants were concentrated by tangential flow filtration using Amicon Ultra-15 100K filters (EMD Millipore, Billerica, MA) at 4,000g for 40 min at 4 °C and stored as aliquots at −80 °C. For HSPC transduction, 1 × 10 5 to 1 × 10 6 FACS-sorted CD34 + CD3 − HSPCs were plated in 6-well nontreated plates coated with 20 µg/ml Retronectin (Clontech, Mountain View, CA) in 1 ml X-VIVO-15 (Lonza, Basel, Switzerland) supplemented with 50 ng/ml of recombinant human stem cell factor (SCF), FLT3L and thyropoietin (TPO), and 10 ng/ml IL-3 (Peprotech, Rocky Hill, NJ) for 12-18 h, after which the lentiviral supernatant was concentrated to a final concentration of 1 × 10 7 to 2 × 10 7 TU/ml. Mock-transduced cells were cultured in identical conditions without the addition of vector. Cells were harvested 24 h after transduction, washed and seeded into ATOs. For transduction of PB T cells, CD8 + T cells from healthy donors were isolated by magnetic negative selection using the CD8 + T cell Isolation Kit (Miltenyi Biotec) and activated and expanded in AIM V medium with 5% human AB serum with anti-CD3-and anti-CD28-coated beads (ThermoFisher Scientific) and 20 ng/ml IL-2 for 4 d before transduction, as previously described 32 . Transduced T cells were subsequently expanded in the presence of IL-2 (20 ng/ml) before use.
Immunohistochemistry. For hematoxylin and eosin (H&E)stained images, ATOs were embedded in Histogel (ThermoFisher Scientific, Grand Island, NY) and fixed overnight in 10% neutralbuffered formalin (ThermoFisher Scientific, Grand Island, NY). 5-µm sections and H&E staining were performed by the UCLA Translational Pathology Core Laboratory (TPCL). For immunofluorescence imaging, ATOs were isolated by cutting the culture insert around each ATO with a scalpel, followed by embedding the membrane and ATO in Tissue-Tek OCT (VWR Radnor, PA) and freezing on dry ice. 5-µm frozen sections were fixed in 10% neutral-buffered formalin and stained with anti-CD3 (clone UCHT1; BioLegend, San Diego, CA) at a 1:50 dilution overnight at 4 °C followed by incubation with AlexaFluor-594-conjugated anti-mouse IgG (H+L) (Jackson ImmunoResearch, West Grove, PA) at room temperature. H&E-stained and immunofluorescence images were acquired on a Zeiss AzioImager M2 with AxioCam MRM and AxioVision software (Zeiss, Jena, Germany).
T cell cytokine assays. Mature CD8 SP or CD4 SP cells from ATOs were isolated by magnetic negative selection using the CD8 + or CD4 + Isolation Kits (Miltenyi Biotec) and sorted by FACS to further deplete CD45RO + cells (containing immature naive T cells and CD4 ISP precursors). Purified T cell populations were plated in 96-well U-bottom plates in 200 µl AIM V medium (ThermoFisher Scientific, Grand Island, NY) with 5% human AB serum (Gemini Bio-Products, West Sacramento, CA). PMA + ionomycin + protein transport inhibitor cocktail or a control protein transport inhibitor cocktail (eBioscience, San Diego, CA) was added to each well and incubated for 6 h. Cells were stained for CD3, CD4 and CD8 (BioLegend, San Diego, CA), as well as UV455 fixable viability dye (eBioscience, San Diego, CA), before fixation and permeabilization with an intracellular staining buffer kit (eBioscience, San Diego, CA) and intracellular staining with antibodies against IFN-γ, TNF-α, IL-2, IL-4 or IL-17A (BioLegend, San Diego, CA).
T cell activation and proliferation assays. For CFSE proliferation assays, ATO-derived CD8 SP or CD4 SP T cells were isolated by negative selection MACS as described in the T cell cytokine assays subsection (with further FACS purification of CD4 SP T cells as described above) and labeled with 5 µM CFSE (BioLegend, San Diego, CA). Labeled cells were incubated with anti-CD3-and anti-CD28-coated beads (ThermoFisher Scientific, Grand Island, NY) in AIM V medium with 5% human AB serum and 20 ng/ml rhIL-2 (Peprotech, Rocky Hill, NJ), co-stained for CD25 or 4-1BB (BioLegend, San Diego, CA), and analyzed by flow cytometry on day 5. In some experiments, CFSE was substituted for CellTrace Violet (CTV; ThermoFisher) with labeling done as per the manufacturer's protocol. For in vitro cell expansion assays, 5 × 10 3 to 1 × 10 4 ATO-derived CD8 SP or CD4 SP T cells, isolated as described above, were plated in 96-well U-bottom plates in 200 µl and activated (or expanded) with anti-CD3-and anti-CD28coated beads and either 20 ng/ml IL-2 or 5 ng/ml IL-7 and 5 ng/ml IL-15 (Peprotech). Beads were removed on day 4, and fresh medium and cytokines were added every 2-3 d, with re-plating into larger wells as needed. Cells were counted weekly with a hemacytometer. In some experiments, cells were re-stimulated with fresh anti-CD3-and anti-CD28-coated beads on day 14.
Artificial APC (aAPC) cytotoxic T lymphocyte (CTL) priming assay. 1 × 10 5 total ATO-derived CD8 SP T cells were isolated from week 6 TCR-transduced ATOs by MACS, as described above, and co-cultured with K562-derived aAPCs expressing CD80 and singlechain trimers of either HLA-A*02:01-B2M-NY-ESO-1 157-165 or HLA-A*02:01-B2M-MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or with parental K562 cells in 96-well U-bottom plates in 200 µl AIM V with 5% human AB serum at a 2:1 T cell:aAPC ratio for 6 h. Allophycocyanin (APC)conjugated CD107a-specific antibody (BioLegend, San Diego, CA) was added to wells at a 1:50 final dilution together with a protein transport inhibitor cocktail (eBioscience, San Diego, CA) for the duration of culture. Cells were then stained for surface markers, fixed, permeabilized and intracellularly stained for cytokines as described above.
TCR Vβ phenotypic analysis. Total cells from pooled week 7 ATOs or postnatal thymi were stained for CD3, CD4, CD8 and TCR-γδ, in conjunction with the IOTest Beta Mark TCR V Kit (Beckman Coulter, Indianapolis, IN). CD3 + TCR-γδ − CD8 + CD4 − cells were gated for analysis, and Vβ family usage was determined by percentage of FITC + , PE + or FITC + PE + cells, which represented three different Vβ-specific antibodies per tube. For Vβ analysis of TCR-transduced ATOs, total cells from week 6-7 ATOs were additionally labeled with an APC-conjugated HLA-A*02:01-NY-ESO-1 157-165 tetramer (MBL International, Woburn, MA) for 10 min before surface antibody staining, and cells were gated on a CD3 + TCRγδ − tetramer + CD8 + CD4 − phenotype for Vβ analysis.
TCR repertoire sequencing. Total RNA was purified from 40,000-200,000 FACS-sorted ATO or thymic CD3 + TCR-αβ + CD8 SP or PB CD3 + TCR-αβ + CD8 + CD45RO − CCR7 + naive CD8 + T cells using the RNeasy Micro kit (Qiagen) according to the manufacturer's instructions. RNA concentration and quality were determined using the Agilent RNA 6000 Nano chip. A targeted cDNA library comprising rearranged genes encoding the TCR variable regions was prepared by 5′ random amplification of cDNA ends (RACE) using the SMARTer PCR cDNA Synthesis kit (Clontech) with modifications as follows. First-strand cDNA was prepared from 3.5-500.0 ng total RNA using the manufacturer's protocol but substituting a poly-dT primer (5′-T30VN-3′). Double-stranded TCR-α-encoding and TCR-β-encoding cDNA libraries were prepared separately by semi-nested PCR using the Advantage 2 PCR kit (Clontech). Initial amplification of cDNAs encoding TCR-α used 0.5 µl of the first-strand reaction (2.5 µl of 1:5 dilution in TE) with the manufacturer's forward Universal Primer Mix and a pair of reverse primers that bound TRAC (5′-GCCACAGCACTGTTGCTCTTGAAGTCC-3′). Semi-nested amplification of TCR-α-encoding cDNA was conducted with the manufacturer's forward Primer IIA and barcoded reverse primers that bound TRAC (5′-X5GGCAGGGTCAGGGTTCTGGAT-3′, where X5 is a 5-nt sample-specific barcode that enables sample pooling before deep-sequencing). Amplification of TCR-β-encoding cDNA was similar, but initial amplification was performed with a reverse primer that bound TRBC (5′-CCACCAGCTCAGCTCCACGTG-3′), and semi-nested amplification was conducted with barcoded primers that bound TRBC (5′-X5GGGAACACSTTKTTCAGGTCCTC-3′). TCR-α and TCR-β cDNA preparations were cleaned up using the DNA Clean and Concentrator-5 kit (Zymo Research). TCR-α and TCRβ cDNA preparations from up to ten samples were pooled before Illumina adaptor ligation and 2 × 150-bp paired-end sequencing on the MiSeq sequencer (Illumina). TCR rearrangements were identified by aligning reads that included the CDR3-encoding sequence to a custom reference sequence library comprising sequences encoding all human T cell receptor alpha variable (TRAV), T cell receptor alpha joining (TRAJ), T cell receptor beta variable (TRBV), T cell receptor beta diversity (TRBD) and T cell receptor beta joining (TRBJ) molecules contained in the International Immunogenetics Information System (IMGT) database 49 . After de-multiplexing using sample-specific barcodes, reads were aligned to a custom reference database comprising all possible combinations of human TRAV-, TRAJ-, TRBV-, TRBDand TRBJ-encoding sequences downloaded from the IMGT database 49 using BLAT 50 . The best BLAT hits were identified with the pslCDnaFilter utility of the BLAT suite using '-maxAligns = 1 -ignoreIntrons' options, and clonotype frequencies were calculated using custom Perl scripts (available upon request).
In vitro cytotoxicity assays. CD8 SP T cells were isolated from pooled ATOs, as described above, and were activated in 96-well round-bottom plated in AIM V medium with 5% human AB serum, anti-CD3-and anti-CD28-coated beads (ThermoFisher Scientific) and 20 ng/ml IL-2 for 36 h. For extended expansions, cells were cultured in IL-2 for up to 14 d. For cytotoxicity assays, twofold serial dilutions of T cells were plated in 96-well roundbottom plates starting at 1 × 10 5 cells per well in AIM V medium with 5% human AB serum. K562 target cells that were transduced with constructs expressing HLA-A*02:01-NY-ESO-1 157-165 or HLA-A*02:01-MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] single-chain trimers, or U266 multiple myeloma cells, were plated at 5 × 10 4 cells per well. Apoptotic cell death of target cells was quantified by annexin V and DAPI staining at 9 h. The percentage of antigen-specific T cells was
